Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 1

Interventions

pembrolizumab 86Cyclophosphamide 58Carboplatin 57Specimen Handling 55fludarabine 46Nivolumab 45Magnetic Resonance Spectroscopy 44Gemcitabine 41Biopsy 40Bevacizumab 36venetoclax 32Dexamethasone 32Paclitaxel 29Cisplatin 29Pemetrexed 28Injections 28Docetaxel 26atezolizumab 24Ipilimumab 23Capecitabine 22Temozolomide 21Azacitidine 21Rituximab 20Oxaliplatin 20Cetuximab 20Lenalidomide 19Fulvestrant 19abemaciclib 18Fluorouracil 17Vincristine 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × azeliragon × 90 days × Clear all
NCT05635734 2026-05-29

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Cantex Pharmaceuticals

Phase 1/2 Completed
33 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡